Wugen to Present Preclinical Data on WU-NK-101 at the European Hematology Association (EHA) 2022 Hybrid Congress
ST. LOUIS, MO and SAN DIEGO, CA, May 12, 2022 –Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological…
Read More